The content on this site is intended for healthcare professionals only
Dr Bhatla speaks with ecancer at EBMCI 2017 about the use of HPV vaccines to prevent cervical cancer and other diseases.
She describes the intended targets of the two HPV vaccines, a bivalent formulation for the most dangerous virus strains and a quadrivalent formulation that aims to prevent additional diseases, and the establishment of a recommended schedule of 2 doses in young girls based on trial data gathered in India.
Dr Bhatla goes on to discuss data from other global trials such as disease reduction in Australian girls, emphasising the affordability of the recommended schedule, and describes serious side effects as not attributable to vaccination.
Reported side effects of HPV vaccination are also discussed by Dr Sudeep Gupta and Dr Supriya Chopra, and Dr Jaydip Bhaumik spoke with ecancer about the role of community in vaccine adoption.
Synthetic biology and precision medicine in blood and gynaecological cancers
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
